The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

cgsys.com

Founded Year

1995

Stage

Grant | Alive

Total Raised

$28.95M

Last Raised

$14.7M | 2 mos ago

About Copernicus Therapeutics

Copernicus Therapeutics is a clinical-stage biopharmaceutical company in the emerging field of precision medicine and gene therapy. The company is based in Cleveland, Ohio.

Copernicus Therapeutics Headquarter Location

11000 Cedar Avenue Suite 145

Cleveland, Ohio, 44106,

United States

216-231-0227

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Copernicus Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Copernicus Therapeutics is included in 2 Expert Collections, including Renewable Energy.

R

Renewable Energy

3,920 items

This collection contains upstream and downstream solar companies, as well as those who manufacture and sell products that are powered by solar technology.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Copernicus Therapeutics Patents

Copernicus Therapeutics has filed 6 patents.

The 3 most popular patent topics include:

  • Driver distraction
  • Neuropsychological tests
  • Psychological testing
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/30/2019

5/19/2020

Road safety, Driver distraction, Neuropsychological tests, Psychological testing, Vehicle law

Grant

Application Date

7/30/2019

Grant Date

5/19/2020

Title

Related Topics

Road safety, Driver distraction, Neuropsychological tests, Psychological testing, Vehicle law

Status

Grant

Latest Copernicus Therapeutics News

Global Nucleic Acid Based Gene Therapy Market Research Report 2021 Featuring Wave Life Sciences, Imugene, Caperna, Phylogica, Benitec, EGEN, BioMedica, Transgene and Copernicus Therapeutics

Feb 7, 2022

Major players in the nucleic acid-based gene therapy market are Wave Life Sciences, Imugene, Caperna, Phylogica, Protagonist Therapeutics, Benitec Biopharma, EGEN, BioMedica, Transgene and Copernicus Therapeutics. The global nucleic acid based gene therapy market is expected to grow from $0.56 billion in 2020 to $0.61 billion in 2021 at a compound annual growth rate (CAGR) of 8.9%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $0.85 billion in 2025 at a CAGR of 9%. The nucleic acid-based gene therapy market consists of sales of nucleic acid-based gene therapy products and services. Gene therapy is used for correcting defective genes that are responsible for disease development. Moreover, nucleic acid-based therapeutics are used to treat genetic disorders and diseases for which there exists no permanent cure such as anaemia, sickle cell, cystic fibrosis, diabetes, and thalassemia. Stringent regulations imposed on gene therapies raises the price of gene therapies, which in turn hinders the demand for nucleic acid-based gene therapies. The excessive regulatory oversights create an expensive and elongated route for approval increasing the expenses. According to Foundation for Economic Education (FEE), unlike other drugs approved or regulated by the Food and Drug Administration (FDA), gene therapies are not only subject to the regulatory structure of FDA, but also the Recombinant DNA Advisory Committee and Office of Biotechnology Activities. Also, as estimated by FEE, an approved gene therapy drug cost nearly $5.0 billion, which is five times higher than that of the average cost of FDA approval. The high cost of gene therapeutics drugs places them beyond the financial reach of the populace. This scenario is anticipated to restrain the market growth of the nucleic acid-based gene therapy market. Rising financial support by the government and the companies is projected to drive the demand for nucleic acid based gene therapy. Nucleic acid therapeutics are analogs of naturally occurring acids or proteins responsible for genetic expression. The traditional therapies do not have any cure for the treatment of diseases such as cystic fibrosis, hemophilia, sickle cell anaemia, thalassemia, and diabetes. Genetic profiling and molecular target identification form the backbone of these classes of drugs. Nucleic acid medication has greater potential for the treatment of these diseases, as they target the genetic basis of diseases and have a permanent cure. Rising financial support by the government and the companies dealing in the market for gene therapy is expected to contribute to increasing the demand for nucleic acid-based gene therapies. The government support for gene therapies will contribute to the growth of the market. Key Topics Covered: 3. Nucleic Acid Based Gene therapy Market Trends and Strategies 4. Impact Of COVID-19 On Nucleic Acid Based Gene therapy 5. Nucleic Acid Based Gene therapy Market Size and Growth 5.1. Global Nucleic Acid Based Gene therapy Historic Market, 2015-2020, $ Billion 5.1.1. Drivers Of the Market 5.1.2. Restraints On the Market 5.2. Global Nucleic Acid Based Gene therapy Forecast Market, 2020-2025F, 2030F, $ Billion 5.2.1. Drivers Of the Market 5.2.2. Restraints On the Market 6. Nucleic Acid Based Gene therapy Market Segmentation 6.1. Global Nucleic Acid Based Gene therapy Market, Segmentation by Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion Anti-Sence and Anti-Gene

  • When was Copernicus Therapeutics founded?

    Copernicus Therapeutics was founded in 1995.

  • Where is Copernicus Therapeutics's headquarters?

    Copernicus Therapeutics's headquarters is located at 11000 Cedar Avenue, Cleveland.

  • What is Copernicus Therapeutics's latest funding round?

    Copernicus Therapeutics's latest funding round is Grant.

  • How much did Copernicus Therapeutics raise?

    Copernicus Therapeutics raised a total of $28.95M.

  • Who are the investors of Copernicus Therapeutics?

    Investors of Copernicus Therapeutics include National Institutes of Health and Vivo Capital.

  • Who are Copernicus Therapeutics's competitors?

    Competitors of Copernicus Therapeutics include Standard Solar, Trina Solar, Ice Energy, Clean Power Finance, Accustrata and 13 more.

You May Also Like

O
Octillion Corporation

Octillion Corp., together with its wholly owned subsidiaries, is a technology incubator focused on the identification, acquisition, development, and commercialization of alternative and renewable energy technologies. Through established relationships with universities, research institutions, government agencies and start-up companies, the company strive to identify technologies and business opportunities on an edge of innovation that have the potential of serving and unmet market needs. nOnce a technology has been identified, the company fund the research and development activities relating to the technology with the intention of ultimately, if warranted, licensing, commercializing and marketing the subject technology, either through internal resources, collaborative agreements or otherwise. Unique to the company's business model is the use of established research infrastructure owned by the various organizations the company deal with, saving us capital which would otherwise be required for such things as land and building acquisition, equipment and furniture purchases, and other incidental start up costs. As a result, the company are able to conduct research in development. nnAmong the company's current research and development activities is the development of a patent-pending technology that could adapt existing home and office glass windows into ones capable of generating electricity from solar energy without losing transparency or requiring major changes in manufacturing infrastructure. The company are also developing a system to harness the kinetic energy of vehicles in motion as part of a broader effort to enhance the sustainability and energy efficiency of transportation infrastructures and systems.

Camstar Systems Logo
Camstar Systems

As the Solar Energy industry continues to emerge, new factories, new markets and new competitors place pressure on suppliers to meet ever higher demand for volume and quality. No longer can Solar manufacturers rely on legacy systems or manual methods of lot tracking. Today, Solar manufacturers need systems that can efficiently track, trace and control this high-volume production. Customer orders need to be visible to guarantee on-time delivery, and engineers need to collect data that will help them to improve quality and yields. Full-featured and ScalablennSolar Cell manufacturing includes high volume silicon wafer processing, electronic assembly, component tracking, vendor compliance and ultimately cell testing and rating. To manage these complex processes, Solar manufacturers need detailed data for analysis and control of a Wafer Fab, combined with visibility and traceability of the complex and high production volumes of Assembly and Test. When time-to-volume can make the difference in gaining market leadership, implementing a first-class, production-ready Manufacturing Execution System (MES) translates to a bigger share of the future. With Camstar's Solar Suite , Solar manufacturers get the power and control of the Fab combined with the dynamic tracking of Assembly and Test in a single Manufacturing Execution System. Camstar's solutions have long been a choice for Semiconductor and Electronics manufacturers, and Solar Edition is specifically designed to meet the needs of both the wafer processing and the electronic assembly. Out-of-the-box functionality translates to faster implementation and greater capability so users can have a first-class manufacturing solution that doesn't slow users down.

Orb Energy Logo
Orb Energy

Orb Energy is a residential and commercial solar system integrator and financier and installer.

G
Gratings Incorporated

Gratings Incorporated is a company that received a STTR Phase I grant for a project entitled: High Efficiency Thin-film Photovoltaics on Low-cost Substrates by Layer Transfer. Their their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will apply high aspect ratio, nm-scale, columnar, and crystalline Si structures as templates for high-quality growth of thin-film GaAs solar cells on low-cost flexible substrates. Sub-10-nm Si seed layers are expected to facilitate growth of low-defect density GaAs films. The aspect ratio of nm-scale structures also serve as sacrificial layers for removal of completed GaAs solar cell. Epitaxial growth and characterization of GaAs films on nm-scale Si structures will be carried out at the Center for High Technology at the University of New Mexico. Successful phase I STTR research will lead to commercialization of high (~ 20 %) efficient, flexible solar cells for applications in a wide range of terrestrial and space environments. Multiple substrate re-use and inherent large area processing capability of Si will result in significant cost reductions. High quality heteroepitaxial GaAs growth on Si has been a subject of intense research. Due to its direct bandgap, GaAs is attractive for a number of optoelectronics applications and its integration with Si-based microelectronics has been a cherished goal. The lattice and thermal expansion mismatches with Si make it difficult to grow good device quality layers. We have recently demonstrated as the Si seed dimension is reduced below 100 nm dimensions, the quality of heteroepitaxial growth increases rapidly. The nm-scale Si structures are formed using low-cost, large area methods based on conventional integrated circuit processing methods. Successful research effort will lead to reduction in PV generation costs, and enhanced applicability of thin-film PV in terrestrial and space environments because in contrast with competing thin-film solar cells, GaAs thin-film solar cells will not suffer from light-induced performance degradation.

A
Ambp Technology Corporation

Ambp Technology Corporation is a company that received a SBIR Phase I grant for a project entitled: Photovoltaic Laser Annealing System. Their project proposes to achieve recently reported gains in CIGS solar cell efficiency from in-situ laser deposition, by using an ex-situ laser annealing approach that is compatible with an existing pilot manufacturing system. The proposed ex-situ approach will not need to heat the substrate above the 425C value used to manufacture CIGS solar cells on flexible polyimide substrates. Solar cell technology is an energy alternative that can reduce America's dependence on fossil-fuel-generated electric power. A truly cost effective technology is to build cells using methods whose thermal budgets are low enough to enable the use of inexpensive polymer substrates, which enables large-area roll-to-roll processing and automated cell-to-cell connection techniques. AMBP Tech Corporation will develop and demonstrate a tool to improve solar cell performance that is immediately applicable in the solar-cell manufacturing marketplace.

T
Tisol

Tisol is a company that received a SBIR Phase I grant for a project entitled: Scalable fabrication of mesoporous thin-films for production of efficient dye-sensitized solar cells. Their project aims to apply a specialized method to develop a rapid, large-scale and inexpensive thin film deposition technology. The goal is to enable the low-cost mass production and maintain the optimized nanostructures and film properties of efficient dye-sensitized solar cells. The broader societal/commercial impact of this project will be the potential to reduce production costs of materials used in dye-sensitized solar cells. Compared to other solar cell technologies, dye-sensitized solar cell technology has the potential of (1) low cost due to the abundance of elements that constitute the cell; (2) lightweight thus reduced installation cost and enhanced flexibility. However, recent advances in photovoltaics industry set a cost standard of < $1/Watt. If dye-sensitized solar cells were to be at par with current technologies on the market, the cost of thin film deposition has to be reduced. This project targets on the development of a high-throughput and large-scale thin film deposition process, which will make the solar electricity via dye-sensitized technology more cost-effective and thus more available.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.